Emerging drugs for the treatment of inflammatory bowel disease.

Wong, Uni; Cross, Raymond K

Wong, Uni; Cross, Raymond K.

Affiliation

Wong U; University of Maryland School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Baltimore, Maryland, USA.
Cross RK; University of Maryland School of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, Baltimore, Maryland, USA.

Expert Opin Emerg Drugs ; 27(4): 369-377, 2022 12.

Article in En | MEDLINE | ID: mdl-36369862

Subject(s)

Colitis, Ulcerative; Inflammatory Bowel Diseases; Humans; Tumor Necrosis Factor Inhibitors/therapeutic use; Inflammatory Bowel Diseases/drug therapy; Tumor Necrosis Factor-alpha; Interleukin-23; Colitis, Ulcerative/drug therapy

Key words

Crohn's disease; JAK inhibitor; S1P receptor modulator; anti-IL12/23; anti-IL23; anti-TNF; anti-integrin; mRNA-124; ulcerative colitis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases / Colitis, Ulcerative Type of study: Guideline Limits: Humans Language: En Journal: Expert Opin Emerg Drugs Journal subject: TERAPIA POR MEDICAMENTOS Year: 2022 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google